Department of Nephrology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Front Endocrinol (Lausanne). 2022 Jun 3;13:871272. doi: 10.3389/fendo.2022.871272. eCollection 2022.
Diabetic kidney disease (DKD) is one of most common complications of diabetes. Recently, the classical phenotype of DKD, which is characterized by albuminuria preceding renal insufficiency, has been challenged since a subset of diabetic patients with renal insufficiency but without albuminuria has been increasingly reported. However, the available evidence is inconsistent. Thus, the present systematic review will assess and summarize the available data regarding nonalbuminuric diabetic kidney disease (NADKD).
PubMed, Embase, and Cochrane were searched for clinical trials related to NADKD. The results were limited to full-text articles published in English, without restrictions on the publication time. The quality of clinical trials was appraised, and the data were extracted. Meta-analysis was conducted using a random-effects model. Descriptive analysis was performed if the data were insufficient.
A final total of 31 articles were included in this review. The meta-analysis of 18 studies showed that compared with albuminuric DKD, patients with NADKD were older ( = 1.04 years old, 95% CI [0.52, 1.57], < 0.05); were more often women (Male = 0.74, 95% CI [0.68, 0.81], < 0.05); had shorter diabetes duration ( = 2.9 years, 95% CI [-3.63, -2.18], < 0.05), lower HbA1c levels ( = 0.34%, 95% CI [-0.42, -0.25], < 0.05), and lower blood pressure (systolic blood pressure = 6.21 mmHg, 95% CI [-9.41, -3.0], < 0.05; diastolic blood pressure = 1.27 mmHg, 95% CI [-2.15, 4.0], < 0.05); less frequently experienced diabetic retinopathy ( = 0.58, 95% CI [0.51, 0.67], < 0.05); and less frequently used renin-angiotensin-aldosterone system (RAAS) inhibitors. The underlying pathology of NADKD might be different from that of the classic phenotype of DKD, which is associated with more advanced tubulointerstitial and vascular lesions but mild typical glomerular lesions. The annual estimated glomerular filtration rate decline tended to be lower in patients with NADKD than in those with albuminuric DKD. The risk for cardiovascular disease, end-stage renal disease, and all-cause death was lower for patients with NADKD than patients with albuminuric DKD.
The prevalence of NADKD has increased in recent decades, and its characteristics, pathology, and prognosis are different from those of albuminuric DKD; thus, diagnosis and treatment strategies should be different. More attention should be given to this phenotype.
糖尿病肾病(DKD)是糖尿病最常见的并发症之一。最近,DKD 的经典表型(其特征为白蛋白尿先于肾功能不全)受到了挑战,因为越来越多的肾功能不全但无白蛋白尿的糖尿病患者被报道。然而,现有的证据并不一致。因此,本系统综述将评估和总结有关非白蛋白尿性糖尿病肾病(NADKD)的现有数据。
在 PubMed、Embase 和 Cochrane 中检索与 NADKD 相关的临床试验。结果仅限于全文发表于英文文献,且不限制出版时间。评价临床试验的质量,并提取数据。使用随机效应模型进行荟萃分析。如果数据不足,则进行描述性分析。
本综述共纳入 31 篇文章。对 18 项研究的荟萃分析显示,与白蛋白尿性 DKD 患者相比,NADKD 患者年龄更大( = 1.04 岁,95%CI [0.52, 1.57], < 0.05);更多为女性(男性 = 0.74,95%CI [0.68, 0.81], < 0.05);糖尿病病程更短( = 2.9 年,95%CI [-3.63, -2.18], < 0.05),糖化血红蛋白水平更低( = 0.34%,95%CI [-0.42, -0.25], < 0.05),血压更低(收缩压 = 6.21mmHg,95%CI [-9.41, -3.0], < 0.05;舒张压 = 1.27mmHg,95%CI [-2.15, 4.0], < 0.05);更少发生糖尿病视网膜病变( = 0.58,95%CI [0.51, 0.67], < 0.05);更少使用肾素-血管紧张素-醛固酮系统(RAAS)抑制剂。NADKD 的潜在病理可能与 DKD 的经典表型不同,其与更严重的肾小管间质和血管病变有关,但肾小球典型病变较轻。与白蛋白尿性 DKD 患者相比,NADKD 患者的估计肾小球滤过率年下降趋势较低。与白蛋白尿性 DKD 患者相比,NADKD 患者的心血管疾病、终末期肾病和全因死亡风险较低。
近年来,NADKD 的患病率有所增加,其特征、病理和预后与白蛋白尿性 DKD 不同;因此,诊断和治疗策略也应不同。应更加关注这一表型。